Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1366-1371.
• Review • Previous Articles Next Articles
Received:2025-11-27
Online:2026-09-30
Published:2026-11-16
| [1] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology,2023,77(4):1335-1347. [2] Tilg H, Adolph T E, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab,2022,34(11):1700-1718. [3] Rong L, Zou J, Ran W,et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol (Lausanne) ,2023,13:1087260. [4] Zhao Z H, Wang Z X, Zhou D, et al. Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene[J]. Cell Mol Gastroenterol Hepatol,2021,12(3):857-871. [5] Huang L J, Wang M Y, Xin F Z, et al. Sodium butyrate ameliorates liver fibrosis in metabolic dysfunction-associated steatohepatitis rats via miR-155-5p/SOCS1/PDGF signaling pathway[J]. Hepatobiliary Pancreat Dis Int,2025,24(4):423-432. [6] Li X, Su C, Jiang Z, et al. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome[J]. NPJ Biofilms Microbiomes,2021,7(1):36. [7] Ding N, Wang K, Jiang H, et al. AGK regulates the progression to NASH by affecting mitochondria complex I function[J]. Theranostics,2022,12(7):3237-3250. [8] Shi C, Pei M, Wang Y, et al. Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine[J]. Biochem Biophys Res Commun,2022,594:1-7. [9] Cao Y N, Yue S S, Wang A Y, et al. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity[J]. J Ethnopharmacol,2022,292:115146. [10] Li F, Jiang C, Krausz K W, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J]. Nat Commun,2013,4:2384. [11] Fiorucci S, Distrutti E. The pharmacology of bile acids and their receptors[J]. Handb Exp Pharmacol,2019,256:3-18. [12] Yang Z H, Liu F, Zhu X R, et al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis[J]. World J Gastroenterol,2021,27(24):3609-3629. [13] Sun Y, Zhu M, Zhao H, et al. Serum fibroblast growth factor 19 and total bile acid concentrations are potential biomarkers of hepatocellular carcinoma in patients with type 2 diabetes mellitus[J]. Biomed Res Int,2020,2020:1751989. [14] Min B H, Devi S, Kwon G H, et al. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation[J].Gut Microbes,2024,16(1):2307568. [15] 张浩原,赵真旺,张敏. 3-吲哚丙酸在代谢性疾病中的研究进展[J].中国病理生理杂志,2024, 40(10): 1957-1962. [16] Li J, Chen X, Song S, et al. Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD[J]. Cell Rep,2025,44(3):115350. [17] Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Mol Nutr Food Res,2019,63(17):e1900257. [18] Zhao M, Zhao J, Yang H, et al. The bile acid-gut microbiota axis: a central hub for physiological regulation and a novel therapeutic target for metabolic diseases[J].Biomed Pharmacother,2025,188:118182. [19] Schnabl B, Damman C J, Carr R M. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations[J].J Clin Invest,2025,135(7):e186423. [20] Lau H C, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol, 2025,22(9):619-638. [21] Wang L, Wang H, Wu J, et al. Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value[J].Front Cell Infect Microbiol,2025,15:1635638. [22] Wang L J, Sun J G, Chen S C, et al. The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies[J].Front Med (Lausanne),2025,11:1490929. [23] Leone V, Gibbons S M, Martinez K, et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism[J].Cell Host Microbe,2015,17(5):681-689. [24] Gutierrez Lopez D E, Lashinger L M, Weinstock G M, et al. Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet[J].Cell Metab,2021,33(5):873-887. [25] Ramos S F, Siguenza N, Zhong W, et al. Metatranscriptomics uncover diurnal functional shifts in bacterial transgenes with profound metabolic effects[J].Cell Host Microbe,2025,33(7):1057-1072. [26] Saran A R, Dave S, Zarrinpar A. Circadian rhythms in the pathogenesis and treatment of fatty liver disease[J].Gastroenterology,2020,158(7):1948-1966.e1. [27] Sundin O H, Mendoza-Ladd A, Zeng M, et al. The human jejunum has an endogenous microbiota that differs from those in the oral cavity and colon[J].BMC Microbiol,2017,17(1):160. [28] Yuan C, Graham M, Staley C, et al. Mucosal microbiota and metabolome along the intestinal tract reveal a location-specific relationship[J].mSystems,2020,5(3):e00055-20. [29] Lkhagva E, Chung H J, Hong J, et al. The regional diversity of gut microbiome along the GI tract of male C57BL/6 mice[J].BMC Microbiol,2021,21(1):44. [30] Huang Z, Boekhorst J, Fogliano V, et al. Distinct effects of fiber and colon segment on microbiota-derived indoles and short-chain fatty acids[J].Food Chem,2023,398:133801. [31] 程薏霏,刘金波,陈丽.代谢功能障碍相关脂肪性肝病的风险因素和发病机制[J].临床内科杂志,2025,42(5):356-360. [32] Sun B, Ding X, Tan J, et al.TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD[J].Clin Mol Hepatol,2024 ,30(4):863-882. [33] Chen L Z, Wang Y R, Zhao Z Z, et al. Intestinal depletion of TM6SF2 exacerbates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through the gut-liver axis[J].J Clin Transl Hepatol,2025,13(6):443-455. [34] Albenberg L G, Wu G D. Diet and the intestinal microbiome: associations,functions, and implications for health and disease[J].Gastroenterology,2014,146(6):1564-1572. [35] Zhang J, Qi H, Li M, et al. Diet mediate the impact of host habitat on gut microbiome and influence clinical indexes by modulating gut microbes and serum metabolites[J].Adv Sci (Weinh),2024,11(19):e2310068. [36] He Y, Wu W, Zheng H M, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models[J].Nat Med,2018,24(10):1532-1535. [37] Lu J, Zhang L, Zhai Q,et al. Chinese gut microbiota and its associations with staple food type, ethnicity, and urbanization[J].NPJ Biofilms Microbiomes,2021,7(1):71. [38] Gaundal L, Myhrstad M C W, Rud I, et al. Gut microbiota is associated with dietary intake and metabolic markers in healthy individuals[J].Food Nutr Res,2022,23:66. [39] Kim H, Nelson P, Nzabarushimana E, et al. Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease[J].Nat Metab,2025,7(7):1476-1492. [40] Zhou S, Li M, Wang P, et al. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis[J].Science,2025,388(6746):eadp5540. [41] Hickey E, Leaves I, Pradhan A,et al. Effects of short-chain fatty acid combinations relevant to the healthy and dysbiotic gut upon candida albicans[J].Curr Microbiol,2025,82(9):420. [42] Weinberger V, Mohammadzadeh R, Blohs M, et al. Expanding the cultivable humanarchaeome: methanobrevibacter intestini sp. nov. and strain Methanobrevibacter smithii 'GRAZ-2' from human faeces[J].Int J Syst Evol Microbiol,2025,75(4):006751. [43] Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease[J].Obes Rev,2021,22(11):e13316. [44] Ni Y, Qian L, Siliceo S L, et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations[J].Cell Metab,2023,35(9):1530-1547.e8. [45] Wang S L, Liang S, Li S Y, et al. Lactobacillus rhamnosus GG attenuates MASLD/MASH progression by modulating gut microbiota and metabolic pathways[J].Front Microbiol, 2025,16:1586678. [46] Alonso-Allende J, Milagro F I, Aranaz P. Health effects and mechanisms of inulin action in human metabolism[J].Nutrients,2024,16(17):2935. [47] Groenewegen B, Ruissen M M, Crossette E, et al. Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial[J].Gut Microbes,2025,17(1):2541035. [48] Nie Q, Luo X, Wang K, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway[J].Cell,2024,187(11):2717-2734.e33. [49] Wu N, Ma Y C, Gong X Q, et al. The metabolite alpha-ketobutyrate extends life span by promoting peroxisomal function in C. elegans[J].Nat Commun,2023,14(1):240. [50] Zhang Y, Wang X, Lin J, et al. A microbial metabolite inhibits the HIF-2α-ceramide pathway to mediate the beneficial effects of time-restricted feeding on MASH[J].Cell Metab,2024,36(8):1823-1838.e6. [51] Luo X, Wang K, Jiang C. Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects[J].Cell Host Microbe, 2025,33(6):836-853. [52] Moon J S, Hong J H, Jung Y J, et al. SGLT-2 inhibitors and GLP-1 receptor agonistsin metabolic dysfunction-associated fatty liver disease[J].Trends Endocrinol Metab,2022,33(6):424-442. [53] Ji L, Gao L, Xue H,et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet Diabetes Endocrinol,2025,13(9):777-789. [54] Jiang J, Gao Y, Wang J,et al. Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism[J].Cell Metab,2025,37(5):1119-1136.e13. [55] Yang W, Jin Q, Xiao D,et al. Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota[J].Front Microbiol,2025,16:1597995. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||